HK1162150A1 - Reduction of amyloid beta load in non brain tissue - Google Patents

Reduction of amyloid beta load in non brain tissue

Info

Publication number
HK1162150A1
HK1162150A1 HK12102739.8A HK12102739A HK1162150A1 HK 1162150 A1 HK1162150 A1 HK 1162150A1 HK 12102739 A HK12102739 A HK 12102739A HK 1162150 A1 HK1162150 A1 HK 1162150A1
Authority
HK
Hong Kong
Prior art keywords
reduction
brain tissue
amyloid beta
beta load
non brain
Prior art date
Application number
HK12102739.8A
Other languages
English (en)
Chinese (zh)
Inventor
J Gregor Sutcliffe
Floyd E Bloom
Brian S Hilbush
Original Assignee
Modgene Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modgene Llc filed Critical Modgene Llc
Publication of HK1162150A1 publication Critical patent/HK1162150A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
HK12102739.8A 2008-11-13 2012-03-19 Reduction of amyloid beta load in non brain tissue HK1162150A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11445908P 2008-11-13 2008-11-13
US23092609P 2009-08-03 2009-08-03
PCT/US2009/064430 WO2010057020A2 (en) 2008-11-13 2009-11-13 Modification of amyloid-beta load in non-brain tissue

Publications (1)

Publication Number Publication Date
HK1162150A1 true HK1162150A1 (en) 2012-08-24

Family

ID=42165803

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102739.8A HK1162150A1 (en) 2008-11-13 2012-03-19 Reduction of amyloid beta load in non brain tissue

Country Status (14)

Country Link
US (2) US20100120787A1 (xx)
EP (1) EP2365804B1 (xx)
JP (2) JP2012508770A (xx)
CN (1) CN102271669A (xx)
AU (1) AU2009313851A1 (xx)
CA (1) CA2742771A1 (xx)
DK (1) DK2365804T3 (xx)
ES (1) ES2543987T3 (xx)
HK (1) HK1162150A1 (xx)
HU (1) HUE027027T2 (xx)
MX (1) MX2011004891A (xx)
PL (1) PL2365804T3 (xx)
PT (1) PT2365804E (xx)
WO (1) WO2010057020A2 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
JP5559043B2 (ja) * 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
EP2166858A4 (en) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc NEW HETEROCYCLIC COMPOUNDS AND ITS USE
PL2949666T3 (pl) 2008-12-19 2019-07-31 Biogen International Neuroscience Gmbh Ludzkie przeciwciała przeciwko alfa-synukleinie
WO2012080703A1 (en) * 2010-12-15 2012-06-21 Cipla Limited Pharmaceutical composition comprising imatinib
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
US9707231B2 (en) * 2011-11-01 2017-07-18 Modgene, Llc Compositions and methods for reduction of amyloid-beta load
WO2013113012A2 (en) 2012-01-27 2013-08-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for profiling and quantitating cell-free rna
WO2015120065A1 (en) * 2014-02-05 2015-08-13 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce apoc3 levels and plasma triglycerides
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CN105018484B (zh) * 2015-07-31 2017-10-13 北京泱深生物信息技术有限公司 Crtap基因及其表达产物作为阿尔茨海默病的诊治靶标
CN105651840B (zh) * 2016-04-01 2017-12-26 商丘师范学院 一种检测β‑淀粉样蛋白寡聚体的类免疫电化学传感器及其制备方法
EA202090555A1 (ru) 2017-08-22 2020-06-08 Байоджен Ма Инк. Фармацевтические композиции, содержащие антитела к бета-амилоиду

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2126451A1 (en) * 1991-12-24 1993-07-08 Brett P. Monia Compositions and methods for modulating .beta.-amyloid
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ATE198622T1 (de) * 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
JP4095895B2 (ja) * 2000-12-01 2008-06-04 マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． Ｒｎａ干渉を媒介する短鎖ｒｎａ分子
US7910586B2 (en) * 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
EP2314691A3 (en) * 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
WO2007019273A2 (en) * 2005-08-04 2007-02-15 Albert Einstein College Of Medicine Of Yeshiva University Phosphorylation of tau by abl
US20090017112A1 (en) * 2006-03-01 2009-01-15 Roskamp Research Llc Compounds for Inhibiting Beta-Amyloid Production
WO2007139120A1 (ja) * 2006-05-30 2007-12-06 Osaka University アミロイドβクリアランス促進剤
JP5675344B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのニトロビニルジアミン誘導体

Also Published As

Publication number Publication date
US20160287587A1 (en) 2016-10-06
MX2011004891A (es) 2011-10-06
DK2365804T3 (en) 2015-07-27
US20100120787A1 (en) 2010-05-13
PL2365804T3 (pl) 2015-10-30
AU2009313851A1 (en) 2010-05-20
JP2015172061A (ja) 2015-10-01
JP2012508770A (ja) 2012-04-12
WO2010057020A2 (en) 2010-05-20
CN102271669A (zh) 2011-12-07
ES2543987T3 (es) 2015-08-26
EP2365804A2 (en) 2011-09-21
WO2010057020A3 (en) 2010-11-25
CA2742771A1 (en) 2010-05-20
HUE027027T2 (en) 2016-08-29
EP2365804B1 (en) 2015-05-06
PT2365804E (pt) 2015-09-16

Similar Documents

Publication Publication Date Title
HK1162150A1 (en) Reduction of amyloid beta load in non brain tissue
HRP20181803T1 (hr) Serumski amiloidni p derivati i njihova priprava i uporaba
EP2244712A4 (en) IN VIVO EXAMINATIONS OF CRYSTALLINE FORMS OF MELOXICAM
IL208458A0 (en) Compositions and methods for skin care
ZA201100974B (en) Treatment of autoimmune and inflammatory disease
IL216128A (en) Antibodies to ngf with increased in vivo stability
EP2338457A4 (en) MEDICAL BED
EP2240017A4 (en) CEONIC BODIES AND ESTERS OF CERAMIC BODIES SUITABLE AS BLOOD HYPOLIPEMENTS
PL2647337T3 (pl) Urządzenie wywołujące bodźce skóry
HK1184053A1 (zh) 用於皮膚增强的蘆薈製劑
HK1156867A1 (en) External preparation for skin
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
GB0908193D0 (en) Treatment of disease state
EP2408740A4 (en) COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND PAIN
EP2405928A4 (en) Methods of treatment and diagnosis for hypersensitivity disorders
IL214133A0 (en) Skin treatment
GB0918392D0 (en) Diagnostic and therapeutic methods
HK1157228A1 (en) Compositions and methods of treating amyloid disease
EP2198040A4 (en) IN VIVO FIGURE OF MYELIN
EP2488198A4 (en) TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS
GB0917612D0 (en) In vivo imaging agents
GB0908101D0 (en) Treatment of stress
ZA201005770B (en) The treatment of damaged skin
GB0901175D0 (en) The treatment of skin aging
EP2515830A4 (en) COMPOSITIONS AND METHODS FOR INCREASING CELL GREASE AND SKIN LAUNDERING

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20201109